CymaBay Therapeutics Inc. (CBAY) News
Filter CBAY News Items
CBAY News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CBAY News Highlights
- For CBAY, its 30 day story count is now at 6.
- Over the past 13 days, the trend for CBAY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about CBAY are DRUG and DEC.
Latest CBAY News From Around the Web
Below are the latest news stories about CYMABAY THERAPEUTICS INC that investors may wish to consider to help them evaluate CBAY as an investment opportunity.
Why CymaBay Morphed From Dollar Stock To Biotech RocketCymaBay is sprinting to the finish line with a treatment for a serious liver disease and CBAY stock is on a massive run. |
Industry Analysts Just Upgraded Their CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Revenue Forecasts By 32%Celebrations may be in order for CymaBay Therapeutics, Inc. ( NASDAQ:CBAY ) shareholders, with the analysts delivering... |
Insider Sell Alert: CymaBay Therapeutics Inc's President of R&D Charles Mcwherter Sells ...In a recent transaction on December 18, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,332 shares of the company's stock. |
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEWARK, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to four employees on December 15, 2023 (the “Grant Date”) in connection with the employees’ commencement of employment at CymaBay. The Compensation Committee of the Board of Directors of CymBay approved the grant of non-qualif |
Vice President Daniel Menold Sells 21,497 Shares of CymaBay Therapeutics Inc (CBAY)In a recent transaction on December 15, 2023, Daniel Menold, the Vice President of Finance at CymaBay Therapeutics Inc, sold 21,497 shares of the company's stock. |
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary CholangitisCymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational treatment, seladelpar, for the management of primary biliary cholangitis, including pruritus in adults without cirrhosis or with compensated cirrhosis (Child Pugh A) who are inadequate responders or intolerant to urs |
Top Stocks for December 2023The top stocks have the performance of well-run companies, a steady performance, and the potential for future growth. In addition, top stocks turn over more shares and thus have plenty of liquidity to reduce your transaction costs. Investors often compare top stocks against the Russell 3000 Index, a broad measure of the U.S. stock market comprising 3,000 large publicly traded companies or 96% of the investable U.S. equity market. |
Insider Sell Alert: President of R&D Charles Mcwherter Sells 11,342 Shares of CymaBay ...In a recent transaction on November 17, 2023, Charles Mcwherter, the President of Research and Development at CymaBay Therapeutics Inc (NASDAQ:CBAY), sold 11,342 shares of the company's stock. |
Insider Sell Alert: CEO Sujal Shah Divests 64,863 Shares of CymaBay Therapeutics IncIn a notable insider transaction, CEO Sujal Shah of CymaBay Therapeutics Inc (NASDAQ:CBAY) sold 64,863 shares of the company on November 13, 2023. |
CymaBay Announces an Oral Presentation of Seladelpar Phase 3 Pivotal Results in Primary Biliary Cholangitis at the Late Breaker Session of the Liver Meeting®CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPAR𝛿 agonist, in adult patients with primary biliary cholangitis (PBC) will be featured as an oral presentation in today's Late Breaker Session of the American Association for the Study of Liver Di |